Across TCGA pan-cancer cohorts, KRTAP21-2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated KRTAP21-2 data layer compared with 16 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher KRTAP21-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated KRTAP21-2 expression acts as an unfavorable survival marker.

LGG and LIHC are the cancer types where KRTAP21-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	DFS	Median	All	0.159	0.739	<.001	14	view →
LIHC	DFS	Median	All	0.054	0.553	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: KRTAP21-2 tumor-vs-normal RNA expression · all KRTAP21-2 data types